Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒)

Qian  Li-qi; Pei Xiao-hua; Xu Zhi-yin; Wang Chi

doi:10.1007/s11655-007-0120-y

Your Location：

Home >

Browse articles >

Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒)

Updated：2021-08-27

- Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒)
- Chinese Journal of Integrative Medicine Vol. 13, Issue 2, Pages: 120-124(2007)
- Affiliations：
  
  1. Department of TCM, The First Affiliated Hospital of the General Hospital of PLA,Beijing,China
  2. Dongzhimen Hospital Affiliated to Beijing University of TCM,China
  3. Jiangsu Provincial Hospital of TCM,China
  4. Department of Pharmaceutics, The First Affiliated Hospital of the General Hospital of PLA,China
- Author bio：
- Funds：
  
  Supported by The First Affiliated Hospital of the General Hospital of PLA (No. ZZ2004020)
- DOI：10.1007/s11655-007-0120-y
  CLC：
- Published：2007，
Scan for full text
Qian, Lq., Pei, Xh., Xu, Zy. et al. Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒)., Chin. J Integ. Med. 13, 120–124 (2007). https://doi.org/10.1007/s11655-007-0120-y

Qian Li-qi, Pei Xiao-hua, Xu Zhi-yin, et al. Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒). [J]. Chinese Journal of Integrative Medicine 13(2):120-124(2007)
Qian, Lq., Pei, Xh., Xu, Zy. et al. Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒)., Chin. J Integ. Med. 13, 120–124 (2007). https://doi.org/10.1007/s11655-007-0120-y DOI：

Qian Li-qi, Pei Xiao-hua, Xu Zhi-yin, et al. Clinical observation on treatment of hyperplasia of mammary gland by Lirukang Granule (利乳康颗粒). [J]. Chinese Journal of Integrative Medicine 13(2):120-124(2007) DOI： 10.1007/s11655-007-0120-y.

摘要

To explore the efficacy and mechanism of Lirukang Granule (利乳康颗粒

LRKG) in treating hyperplasia of mammary gland (HMG). One hundred patients with HMG were randomly assigned to two groups

50 in each group. The patients in the treated group were orally administered with LRKG thrice a day

one package each time

and those in the control group were given orally Rukuaixiao Tablet (乳块消

RKX) thrice a day

4 tablets each time. The therapeutic course for both groups was 4 months. The clinical efficacy

pain alleviating rate

as well as changes of local sign and symptom scores were observed before and after treatment. The changes of serum estradiol (E2)

progesterone (P)

testosterone (T)

follicle stimulating hormone (FSH)

luteinizing hormone (LH) and prolactin (PRL) in some randomly selected patients (24 patients in the treated group and 24 in the control group) before and after treatment were measured with radioimmunoassay. The total clinical efficacy in the treated group was superior to that in the control group

significant difference was shown between the two groups (P < 0.01). The cure-effective rate and total effective rate in the treated group were 70.0% and 88.0% respectively

significantly higher than those in the control group (38.0% and 64.0%) respectively (P < 0.01)

and the pain alleviating rate in the treated group was also significantly higher in the former than that in the latter (88.0% vs 64.0%

P < 0.05). Moreover

the treated group showed obvious superiority in improving the patients’ symptom and sign scores (P < 0.01)

and abnormalities of gonadal hormone as compared with the respective items in the control group (P < 0.01). LRKG has good efficacy in the treatment of HMG

and its mechanism may be related to the regulation on endocrine and immune function.

Abstract

To explore the efficacy and mechanism of Lirukang Granule (利乳康颗粒

LRKG) in treating hyperplasia of mammary gland (HMG). One hundred patients with HMG were randomly assigned to two groups

50 in each group. The patients in the treated group were orally administered with LRKG thrice a day

one package each time

and those in the control group were given orally Rukuaixiao Tablet (乳块消

RKX) thrice a day

4 tablets each time. The therapeutic course for both groups was 4 months. The clinical efficacy

pain alleviating rate

as well as changes of local sign and symptom scores were observed before and after treatment. The changes of serum estradiol (E2)

progesterone (P)

testosterone (T)

follicle stimulating hormone (FSH)

significant difference was shown between the two groups (P < 0.01). The cure-effective rate and total effective rate in the treated group were 70.0% and 88.0% respectively

significantly higher than those in the control group (38.0% and 64.0%) respectively (P < 0.01)

and the pain alleviating rate in the treated group was also significantly higher in the former than that in the latter (88.0% vs 64.0%

P < 0.05). Moreover

the treated group showed obvious superiority in improving the patients’ symptom and sign scores (P < 0.01)

and abnormalities of gonadal hormone as compared with the respective items in the control group (P < 0.01). LRKG has good efficacy in the treatment of HMG

and its mechanism may be related to the regulation on endocrine and immune function.

关键词

hyperplasia of mammary glandtraditional Chinese medicinal therapyLirukang Granule

Keywords

hyperplasia of mammary glandtraditional Chinese medicinal therapyLirukang Granule

references

Hu SF, Chen HF. Survey on risk factors of mammary cancer in patients with mammary hyperplasia and their correlation with Chinese medical syndromes. Shanghai J Tradit Chin Med 2004; 38(5): 10–11.

Li JY, Huang F, Li DX, et al. Immunological mechanism of apoptosis induced by Chinese herbal medicine. Chin J Basic Med Tradit Chin Med 2001; 7(2): 20–22.

Liang W. Progress on the immuno-regulatory action of Chinese herbal medicine. Modern Med Health 2005; 21(6) 674–676.

Cao Y, Nie H, Zhang D, et al. Experimental study on the tumor inhibitory and efficacy enhancing effect of Bushen Huayu Jiedu recipe on sarcoma S180 of mice. Chin J Pract Chin Modern Med 2004; 4(17): 2341–2342.

He L, Xu YH, Liu YP. Thinking path of experimental study on the immuno-regulatory action of Chinese compounds for anti-tumor. J Chin Med Pharm 2003; 31(5): 16–17.

Qian LQ, Pan C, Feng ZQ, et al. Effect of Lirukang Liquid on morphology of mammary gland, uterus and ovary of models with hyperplasia of mammary glands. J Nangjing Univ Tradit Chin Med (Nat Sci) 2005; 21(4): 255–257.

Qian LQ, Pei XH, Chen RM, et al. Effect of Lirukang Oral Liquid on neurotransmitters and estrogen in rats with hyperplasia of mammary gland. Chin J Integr Med 2004; 9(2): 131–133.

Qan LQ, Pei XH, Xu ZY. Effect of Lirukang oral liquid on integral condition of model of mammary gland hyperplasia. J Nangjing Univ Tradit Chin Med (Nat Sci) 2002; 18(3): 167–168.

Ministry of Health, P. R. China. Guiding Principle of Clinical Research on New Drugs of TCM. Vol 3. 1997: 50–51.

Wang MY, editor. Hormone Biochemistry. Beijing: People’s Medical Publishing House, 1987: 35–36.

Que HF, Que ZF, Deng XA. Correlative study on neuroendorine and the typing of mastohyperplasia according to syndrome differentiation. Chin Arch Chin Med 2001; 19(2): 98–99.

Zhou QL, Bao HY, Zhang YW, et al. Studies on therapeutic effect of antler on cystic hyperplasia of breast in the rat II: Studies on mechanism of inhibiting cystichyperplasia. Pharmacol Clin Chin Materia Med 1998; 14(3): 23–25.

Zhang JS, Wang SX. Effect of curcumin on proliferation of human cancer cell lines of BCH, MGC-803 and BEL-7402. Chin J Inform Tradit Chin Med 2001; 8(1): 40–41.

Wang Y, Ma AL, Zhang HZ, et al. Experimental studies on the anitumor effect of oyster extract. Chin J Marine Drugs 1997; 16(1): 18–22.

Wen L, Yuan J. Actions of Lijiang pleione bulbocodioides. Chin J Etho Med Ethnopharm 2003; (3): 180–181.

FULL TEXT LINK

More>

Views

363

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

A randomized trial of chinese medicine lirukang granule (利乳康颗粒) combined with psychological intervention for cyclomastopathy and menoxenia

Related Author

No data

Related Institution

Chinese PLA Postgraduate Medical School

Department of Chinese Medicine, the First Hospital Affiliated to Chinese PLA General Hospital

Japan Friendship Hospital,, China

Chinese PLA Troop

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰